GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery

Posted on by

CAMBRIDGE, Mass., March 12, 2024 /PRNewswire/ — GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it has joined NVIDIA Inception, a program that nurtures…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.